Kite Pharma (KITE) Tops Q1 EPS by 44c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- US stock futures fall as fading Iran peace prospects drive up oil, yields
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Kite Reports First Quarter Financial Results
May 8, 2017 8:00 AM EDTCompleted Submission of Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Kites CAR-T Therapy, Axicabtagene Ciloleucel, in Patients with Aggressive Non-Hodgkin Lymphoma (NHL) Initiated Two New Clinical Studies as Part of an Expanded KTE-C19 Development Program Advanced Additional New Cell Therapy Candidates Toward Clinical Study in 2017 Expanded Cell Therapy Account Management Capabilities in Anticipation of Potential Approval and Launch of Axicabtagene Ciloleucel Completed $409.7 Million Follow-On Offering of Common Stock... More
